Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

Impact · against what's priced in

Profound Medical is seeing a valuation catalyst from CAPTAIN study results showing superior erectile and urinary function preservation compared to robotic prostatectomy. While the stock has rallied 13%, the clinical validation of efficacy endpoints and strong revenue growth targets suggest further upside potential.

PROF+0.60: No priced-in read yet

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

What matters in this story

Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

What matters in this story

Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?

How each ticker is affected

Connected tickers

Track these names every morning.

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

What matters in this story

Next reads from the same story arc

Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

What matters in this story

Next reads from the same story arc

Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?

How each ticker is affected

Connected tickers

Track these names every morning.

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)